Cerevel, a neuroscience venture backed by Pfizer and Bain Capital, will go public in a deal with a blank check company sponsored by Perceptive Advisors, which values the drug developer at $780 million. Goodwin’s Life Sciences and Special Purpose Acquisition Companies (SPACs) teams served as legal adviser to Cerevel. Read the article in Bloomberg Law here.